Insider Holders & Insider Ownership - BeiGene Ltd. (BGNE)

List of insiders holdings for BeiGene Ltd.:
  1. Shares directly owned by the insider.
  2. Shares indirectly owned by the insider.
  3. Total shares owned by the insider (sum of shares directly and indirectly owned).
  4. Total market value if available.
  5. Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Insider Holder NameReport
Date Time		Shares Owned
Directly
Indirectly		Total
Shares Owned		Filing
BAKER BROS. ADVISORS LP
14159 L.P.
Baker Bros. Advisors (GP) LLC
BAKER JULIAN
BAKER FELIX
667 L.P.
Baker Brothers Life Sciences LP
Director
10% Owner		2024-12-10 21:30:34125,276,610
0		125,276,610Form 13D
BAKER BROS. ADVISORS LP
667 L.P.
Baker Bros. Advisors (GP) LLC
Baker Brothers Life Sciences LP
BAKER FELIX
BAKER JULIAN
Director		2024-12-10 21:30:34125,276,610
0		125,276,610Form 13D
HHLR ADVISORS LTD.
HILLHOUSE INVESTMENT MANAGEMENT LTD.
10% Owner		2024-12-04 16:06:080
125,045,741		125,045,741Form 4
OYLER JOHN
Chief Executive Officer		2024-12-17 17:02:4313,079,333
46,060,763		59,140,096Form 4
CB Biotech Investment Ltd
CPEChina Fund L.P.
CITIC PE Associates L.P.
CITIC PE Funds Ltd
10% Owner		2016-02-09 20:07:3519,601,138
0		19,601,138Form 4
AMGEN INC
10% Owner		2021-09-13 19:27:0718,943,802
0		18,943,802Form 4
Wang Xiaodong
Chair, Scientific Advisory Brd		2024-12-12 17:18:098,498,169
5,084,111		13,582,280Form 4
Glazer Donald W.
Director		2024-06-07 16:58:012,752,615
0		2,752,615Form 4
Li Ji
EVP and Gl. Head of Bus. Dev.		2018-03-02 18:41:222,721,000
0		2,721,000Form 4
Peterson Amy C.
CMO, Immuno-oncology		2018-12-19 18:34:101,966,402
0		1,966,402Form 4
Wang Lai
Global Head of R&D		2024-10-01 18:29:57920,920
796,965		1,717,885Form 4
Liang Howard
CFO & Chief Strategy Officer		2021-06-30 16:45:491,553,149
0		1,553,149Form 4
Wu Xiaobin
President, COO & GM China		2024-12-10 20:19:561,083,692
4,000		1,087,692Form 4
Yang Jianxin
Sr. VP, Head of Clinical Dev.		2016-07-15 16:34:25825,000
0		825,000Form 4
Yan Wendy Xiaojun
Sr. VP, Head of Reg. Affairs		2016-07-15 16:30:50825,000
0		825,000Form 4
Wang Julia Aijun
Chief Financial Officer		2024-07-03 17:05:32426,595
0		426,595Form 4
Huang Jane
CMO, Hematology		2021-12-16 17:50:15371,331
0		371,331Form 4
Rosenberg Aaron
Chief Financial Officer		2024-08-13 17:17:19339,534
0		339,534Form 4
Lee Chan Henry
SVP, General Counsel		2024-10-02 19:13:48237,224
0		237,224Form 4
Tang Ke
Director		2017-04-21 16:42:20199,992
0		199,992Form 4
Yuan RuiRong
Chief Medical Officer		2016-02-09 20:08:35130,000
0		130,000Form 4
Malley Thomas
Director		2023-06-20 19:00:29103,671
0		103,671Form 4
HOOPER ANTHONY C
Director		2024-06-07 17:00:4087,906
0		87,906Form 4
Sanders Corazon (Corsee) D.
Director		2024-06-07 16:55:2880,392
0		80,392Form 4
Yi Qingqing
Director		2024-06-07 16:31:1780,106
0		80,106Form 4
Dugan Margaret
Director		2024-06-07 17:02:2680,106
0		80,106Form 4
Riva Alessandro
Director		2024-06-07 16:57:1980,106
0		80,106Form 4
BRANDICOURT OLIVIER
Director		2024-06-07 17:01:3850,492
0		50,492Form 4
Ball Titus B.
Principal Accounting Officer		2024-09-05 17:40:3046,124
0		46,124Form 4
Sharp Shalini
Director		2024-10-02 19:21:1925,389
0		25,389Form 4
Chen Timothy Yung-Cheng
Director		2021-06-21 16:42:0825,298
0		25,298Form 4
su Jingshyh S
Director		2021-06-21 16:34:1225,298
0		25,298Form 4
KRISHANA RANJEEV
Director		2016-02-02 19:14:150
0		0Form 3
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Research GmbH
10% Owner		2018-02-13 16:29:070
0		0Form 13G
GOLLER MICHAEL
Director		2016-02-02 19:40:270
0		0Form 3